Compare ZYME & BLBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | BLBD |
|---|---|---|
| Founded | 2003 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2022 | 2013 |
| Metric | ZYME | BLBD |
|---|---|---|
| Price | $28.10 | $57.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $41.21 | ★ $89.13 |
| AVG Volume (30 Days) | ★ 869.8K | 455.5K |
| Earning Date | 11-09-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 22.78 |
| EPS | N/A | ★ 7.33 |
| Revenue | $105,965,000.00 | ★ $1,480,099,000.00 |
| Revenue This Year | $173.22 | $18.37 |
| Revenue Next Year | $35.07 | $14.95 |
| P/E Ratio | ★ N/A | $7.80 |
| Revenue Growth | ★ 38.87 | 9.87 |
| 52 Week Low | $16.00 | $46.14 |
| 52 Week High | $31.34 | $83.39 |
| Indicator | ZYME | BLBD |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 47.27 |
| Support Level | $22.04 | $54.90 |
| Resistance Level | $29.75 | $57.72 |
| Average True Range (ATR) | 1.05 | 1.61 |
| MACD | 0.21 | 0.38 |
| Stochastic Oscillator | 96.19 | 59.74 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.